{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:14:13Z","timestamp":1793794453497,"version":"4.6.1"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This review focuses on recent advances in the field of cytomegalovirus (CMV). The 2 main strategies for CMV prevention are prophylaxis and preemptive therapy. Prophylaxis effectively prevents CMV infection after solid organ transplantation (SOT) but is associated with high rates of neutropenia and delayed-onset postprophylaxis disease. In contrast, preemptive therapy has the advantage of leading to lower rates of CMV disease and robust humoral and T-cell responses. It is widely used in hematopoietic cell transplant recipients but is infrequently utilized after SOT due to logistical considerations, though these may be overcome by novel methods to monitor CMV viremia using self-testing platforms. We review recent developments in CMV immune monitoring, vaccination, and monoclonal antibodies, all of which have the potential to become part of integrated strategies that rely on viral load monitoring and immune responses. We discuss novel therapeutic options for drug-resistant or refractory CMV infection, including maribavir, letermovir, and adoptive T-cell transfer. We also explore the role of donor factors in transmitting CMV after SOT. Finally, we propose a framework with which to approach CMV prevention in the foreseeable future.<\/jats:p>","DOI":"10.1093\/infdis\/jiz454","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T19:30:07Z","timestamp":1569353407000},"page":"S23-S31","source":"Crossref","is-referenced-by-count":148,"title":["Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence"],"prefix":"10.1093","volume":"221","author":[{"given":"Ghady","family":"Haidar","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"},{"name":"Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boeckh","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"},{"name":"Department of Medicine, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"2020030507500503700_CIT0001","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/QCO.0000000000000409","article-title":"Viral infections in solid organ transplant recipients: novel updates and a review of the classics","volume":"30","author":"Haidar","year":"2017","journal-title":"Curr Opin Infect Dis"},{"key":"2020030507500503700_CIT0002","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-guidelines of the American Society of Transplantation Infectious Diseases community of practice","author":"Razonable","year":"2019","journal-title":"Clinical Transplant"},{"key":"2020030507500503700_CIT0003","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-152-12-201006150-00003","article-title":"Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial","volume":"152","author":"Palmer","year":"2010","journal-title":"Ann Intern Med"},{"key":"2020030507500503700_CIT0004","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","article-title":"Extended valganciclovir prophylaxis in D+\/R","volume":"90","author":"Humar","year":"2010","journal-title":"Transplantation"},{"key":"2020030507500503700_CIT0005","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/bloodadvances.2018016493","article-title":"Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation","volume":"2","author":"Chen","year":"2018","journal-title":"Blood Adv"},{"key":"2020030507500503700_CIT0006","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"2020030507500503700_CIT0007","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/01.tp.0000226071.12562.1a","article-title":"Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis","volume":"81","author":"Limaye","year":"2006","journal-title":"Transplantation"},{"key":"2020030507500503700_CIT0008","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ctr.12686","article-title":"Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis","volume":"30","author":"Beam","year":"2016","journal-title":"Clin Transplant"},{"key":"2020030507500503700_CIT0009","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1399-3062.2012.00723.x","article-title":"Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis","volume":"14","author":"Wiita","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"2020030507500503700_CIT0010","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/TP.0b013e31822fa4b7","article-title":"Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients","volume":"92","author":"Lisboa","year":"2011","journal-title":"Transplantation"},{"key":"2020030507500503700_CIT0011","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/lt.24332","article-title":"Characteristics and outcomes of neutropenia after orthotopic liver transplantation","volume":"22","author":"Alraddadi","year":"2016","journal-title":"Liver Transpl"},{"key":"2020030507500503700_CIT0012","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/tid.12349","article-title":"Increased risk of breakthrough infection among cytomegalovirus donor-positive\/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis","volume":"17","author":"Stevens","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"2020030507500503700_CIT0013","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM198801143180202","article-title":"Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation","volume":"318","author":"Meyers","year":"1988","journal-title":"N Engl J Med"},{"key":"2020030507500503700_CIT0014","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0140-6736(94)91835-X","article-title":"Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group","volume":"343","author":"Prentice","year":"1994","journal-title":"Lancet"},{"key":"2020030507500503700_CIT0015","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1086\/367836","article-title":"Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation","volume":"36","author":"Winston","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020030507500503700_CIT0016","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V99.8.3050","article-title":"Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants","volume":"99","author":"Ljungman","year":"2002","journal-title":"Blood"},{"key":"2020030507500503700_CIT0017","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"key":"2020030507500503700_CIT0018","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"2020030507500503700_CIT0019","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"2020030507500503700_CIT0020","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"2020030507500503700_CIT0021","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1111\/ajt.15135","article-title":"Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection","volume":"18","author":"Cherrier","year":"2018","journal-title":"Am J Transplant"},{"key":"2020030507500503700_CIT0022","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/j.1600-6143.2006.01413.x","article-title":"Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients","volume":"6","author":"Khoury","year":"2006","journal-title":"Am J Transplant"},{"key":"2020030507500503700_CIT0023","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1111\/j.1600-6143.2008.02369.x","article-title":"Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review","volume":"8","author":"Sun","year":"2008","journal-title":"Am J Transplant"},{"key":"2020030507500503700_CIT0024","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/infdis\/jiz181","article-title":"Prospective assessment of cytomegalovirus immunity in high-risk donor-seropositive\/recipient-seronegative liver transplant recipients receiving either preemptive therapy or prophylaxis","volume":"220","author":"Limaye","year":"2019","journal-title":"J Infect Dis"},{"key":"2020030507500503700_CIT0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-6143.2007.02031.x","article-title":"Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation","volume":"8","author":"Reischig","year":"2008","journal-title":"Am J Transplant"},{"key":"2020030507500503700_CIT0026","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1600-6143.2007.02133.x","article-title":"Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial","volume":"8","author":"Kliem","year":"2008","journal-title":"Am J Transplant"},{"key":"2020030507500503700_CIT0027","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/TP.0b013e318238dab3","article-title":"Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial","volume":"93","author":"Witzke","year":"2012","journal-title":"Transplantation"},{"key":"2020030507500503700_CIT0028","article-title":"Preemptive therapy (PET) versus prophylaxis for prevention of cytomegalovirus (CMV) disease in high-risk donor seropositive\/recipient seronegative (D+R\u2013) liver transplant recipients (LTR): a NIH-sponsored, randomized, controlled, multicenter trial","author":"Singh"},{"key":"2020030507500503700_CIT0029","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"Cytomegalovirus in solid organ transplantation","volume":"13","author":"Razonable","year":"2013","journal-title":"Am J Transplant"},{"key":"2020030507500503700_CIT0030","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2010-08-304121","article-title":"Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients","volume":"118","author":"Elmaagacli","year":"2011","journal-title":"Blood"},{"key":"2020030507500503700_CIT0031","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fimmu.2018.00389","article-title":"Potential beneficial effects of cytomegalovirus infection after transplantation","volume":"9","author":"Litjens","year":"2018","journal-title":"Front Immunol"},{"key":"2020030507500503700_CIT0032","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N Engl J Med"},{"key":"2020030507500503700_CIT0033","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","article-title":"A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Kharfan-Dabaja","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2020030507500503700_CIT0034","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1056\/NEJMc1406756","article-title":"CMV prophylaxis in hematopoietic-cell transplantation","volume":"371","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"key":"2020030507500503700_CIT0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann Intern Med"},{"key":"2020030507500503700_CIT0036","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020030507500503700_CIT0037","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1128\/JCM.00316-13","article-title":"Quantitation of cytomegalovirus DNA load in dried blood spots correlates well with plasma viral load","volume":"51","author":"Limaye","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2020030507500503700_CIT0038","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cid\/ciy549","article-title":"Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant recipients: a single-arm open-label phase I clinical trial","volume":"68","author":"Smith","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020030507500503700_CIT0039","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ajt.15315","article-title":"A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients","volume":"19","author":"Kumar","year":"2019","journal-title":"Am J Transplant"},{"key":"2020030507500503700_CIT0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcv.2018.06.009","article-title":"T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients","volume":"105","author":"Gliga","year":"2018","journal-title":"J Clin Virol"},{"key":"2020030507500503700_CIT0041","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/infdis\/jir624","article-title":"Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients","volume":"204","author":"Pipeling","year":"2011","journal-title":"J Infect Dis"},{"key":"2020030507500503700_CIT0042","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1164\/rccm.201504-0733OC","article-title":"Polyfunctional T-cell signatures to predict protection from cytomegalovirus after lung transplantation","volume":"193","author":"Snyder","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2020030507500503700_CIT0043","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/TP.0000000000001094","article-title":"Cytomegalovirus immunoglobulin after thoracic transplantation: an overview","volume":"100","author":"Grossi","year":"2016","journal-title":"Transplantation"},{"key":"2020030507500503700_CIT0044","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01794-16","article-title":"Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients","volume":"61","author":"Ishida","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500503700_CIT0045","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcv.2019.04.007","article-title":"New vaccines and antiviral drugs for cytomegalovirus","volume":"116","author":"Griffiths","year":"2019","journal-title":"J Clin Virol"},{"key":"2020030507500503700_CIT0046","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(84)90930-9","article-title":"Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants","volume":"1","author":"Plotkin","year":"1984","journal-title":"Lancet"},{"key":"2020030507500503700_CIT0047","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"2020030507500503700_CIT0048","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/ajt.14925","article-title":"A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor","volume":"18","author":"Vincenti","year":"2018","journal-title":"Am J Transplant"},{"key":"2020030507500503700_CIT0049","article-title":"A randomised, placebo-controlled Phase 3 study to evaluate the efficacy and safety of ASP0113, a first-in-class, DNA-based vaccine in CMV-seropositive allogeneic haematopoietic cell transplant recipients","author":"Maertens","year":"2019"},{"key":"2020030507500503700_CIT0050","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2352-3026(15)00246-X","article-title":"Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial","volume":"3","author":"Nakamura","year":"2016","journal-title":"Lancet Haematol"},{"key":"2020030507500503700_CIT0051","article-title":"Multi-antigen vaccine (TRIPLEX) based on attenuated poxvirus prevents cytomegalovirus viremia in a multi-center placebo-controlled, double line, randomized phase 2 clinical trial in allogeneic HCT recipients","author":"Aldoss","year":"2019"},{"key":"2020030507500503700_CIT0052","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"2020030507500503700_CIT0053","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020030507500503700_CIT0054","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"El Chaer","year":"2016","journal-title":"Blood"},{"key":"2020030507500503700_CIT0055","article-title":"Letermovir as salvage therapy for CMV infection in transplant recipients [manuscript published online ahead of print 15 May 2019]","author":"Phoompoung","year":"2019","journal-title":"Transplantation"},{"key":"2020030507500503700_CIT0056","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02337-18","article-title":"Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis","volume":"63","author":"Turner","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500503700_CIT0057","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500503700_CIT0058","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3389\/fimmu.2017.01272","article-title":"Virus-specific T cells for the immunocompromised patient","volume":"8","author":"Houghtelin","year":"2017","journal-title":"Front Immunol"},{"key":"2020030507500503700_CIT0059","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood.V128.22.388.388","article-title":"Safety and preliminary efficacy of \u201cready to administer\u201d cytomegalovirus (CMV)-specific T cells for the treatment of patients with refractory CMV infection","volume":"128","author":"Tzannou","year":"2016","journal-title":"Blood"},{"key":"2020030507500503700_CIT0060","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/j.1600-6143.2009.02672.x","article-title":"Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy","volume":"9","author":"Brestrich","year":"2009","journal-title":"Am J Transplant"},{"key":"2020030507500503700_CIT0061","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/cti.2015.5","article-title":"Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation","volume":"4","author":"Holmes-Liew","year":"2015","journal-title":"Clin Transl Immunology"},{"key":"2020030507500503700_CIT0062","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.exger.2007.01.005","article-title":"Chronic herpesvirus reactivation occurs in aging","volume":"42","author":"Stowe","year":"2007","journal-title":"Exp Gerontol"},{"key":"2020030507500503700_CIT0063","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1128\/CMR.2.2.204","article-title":"Acquisition of cytomegalovirus infection: an update","volume":"2","author":"Forbes","year":"1989","journal-title":"Clin Microbiol Rev"},{"key":"2020030507500503700_CIT0064","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1086\/598952","article-title":"An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants","volume":"199","author":"Manuel","year":"2009","journal-title":"J Infect Dis"},{"key":"2020030507500503700_CIT0065","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/tid.12205","article-title":"Transient residence of a seropositive organ is sufficient to transfer human cytomegalovirus to a seronegative recipient","volume":"16","author":"Lumgair","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"2020030507500503700_CIT0066","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/trf.12390","article-title":"Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors","volume":"53","author":"Furui","year":"2013","journal-title":"Transfusion"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/Supplement_1\/S23\/32791376\/jiz454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/Supplement_1\/S23\/32791376\/jiz454.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:01:47Z","timestamp":1721779307000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/221\/Supplement_1\/S23\/5781910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":66,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2020,3,5]]},"published-print":{"date-parts":[[2020,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz454","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3,15]]},"published":{"date-parts":[[2020,3,5]]}}}